Retour sur lavenir.net
   ARGENX SE 690.400 € (+0,79 %)     COLRUYT 33.180 € (-0,42 %)     AGEAS 67.750 € (+1,19 %)     AB INBEV 71.160 € (+1,34 %)     WDP 22.240 € (+1,28 %)     CMB.TECH 14.940 € (+2,47 %)     LOTUS BAKERIES 10 800.000 € (+1,50 %)     D'IETEREN GROUP 164.300 € (-0,06 %)     RETAIL ESTATES 69.700 € (+1,75 %)     NYXOAH 2.485 € (+4,41 %)     AEDIFICA 71.450 € (+5,00 %)     SIPEF 95.000 € (-5,00 %)     XIOR 28.300 € (+0,89 %)     ABO GROUP 4.400 € (0,00 %)     BQUE NAT. BELGIQUE 375.000 € (+4,17 %)     EXMAR 11.100 € (-0,45 %)     VIOHALCO 17.900 € (-1,00 %)     BANQUP GROUP 2.470 € (-0,80 %)     GIMV 48.550 € (+0,83 %)     KBC 110.350 € (+1,38 %)     AGFA-GEVAERT 0.466 € (+1,64 %)     FAGRON 24.700 € (+1,65 %)     ACKERMANS V.HAAREN 277.600 € (+0,07 %)     VASTNED 29.650 € (+0,85 %)     MELEXIS 77.850 € (+4,57 %)     JENSEN-GROUP 72.000 € (0,00 %)     TESSENDERLO 21.050 € (+0,24 %)     SYENSQO 61.050 € (+0,49 %)     KBC ANCORA 77.900 € (+1,70 %)     ONTEX GROUP 2.740 € (+3,20 %)     DEME GROUP 191.200 € (+0,42 %)     IMMOBEL 21.500 € (-2,27 %)     WHAT'S COOKING GP 144.000 € (0,00 %)     EVS BROADC.EQUIPM. 36.800 € (+0,27 %)     ORANGE BELGIUM 21.500 € (0,00 %)     VAN DE VELDE 30.400 € (+0,33 %)     VGP 80.500 € (-0,74 %)     SOFINA 222.400 € (+1,92 %)     COFINIMMO 83.300 € (+4,52 %)     TITAN S.A. 47.460 € (+3,53 %)     ECONOCOM GROUP 1.500 € (0,00 %)     CFE 11.750 € (+2,62 %)     BARCO 9.070 € (+1,11 %)     SHURGARD 24.150 € (+2,11 %)     BREDERODE 102.200 € (+0,99 %)     ENERGYVISION 13.100 € (-0,38 %)     UMICORE 24.420 € (+2,61 %)     CARE PROPERTY INV. 13.220 € (+1,69 %)     TINC 12.060 € (+0,67 %)     CIE BOIS SAUVAGE 319.000 € (+1,27 %)     UCB 238.600 € (+1,58 %)     PROXIMUS 6.925 € (+1,76 %)     GBL 79.400 € (+0,83 %)     KINEPOLIS GROUP 29.300 € (+0,34 %)     MONTEA 70.900 € (+1,14 %)     HOME INVEST BE. 18.800 € (+1,18 %)     RECTICEL 10.540 € (+2,53 %)     SOLVAY 25.300 € (0,00 %)     BEKAERT 40.400 € (+1,51 %)     QUESTFOR GR-PRICAF 3.000 € (+0,74 %)  
   ADYEN 956.300 € (+0,39 %)     FDJ UNITED 22.950 € (-0,74 %)     ARVERNE GROUP 7.000 € (-4,11 %)     CSG 18.700 € (+8,70 %)     PHILIPS KON 22.920 € (+1,55 %)     AIR LIQUIDE 177.020 € (+1,68 %)     SCHNEIDER ELECTRIC 264.600 € (+3,44 %)     AMUNDI 86.050 € (+1,35 %)     COVIVIO 54.500 € (+1,58 %)     DANONE 63.500 € (0,00 %)     KLEPIERRE 34.640 € (+0,46 %)     STMICROELECTRONICS 55.270 € (+5,98 %)     VALEO 12.250 € (+0,12 %)     ALTEN 62.500 € (-1,65 %)     LEGRAND 151.200 € (+3,85 %)     AYVENS 10.810 € (+2,37 %)     EURONEXT 147.600 € (+5,20 %)     EXOR NV 66.450 € (+0,99 %)     BASIC-FIT 30.380 € (+2,01 %)     VIVENDI SE 2.284 € (+1,87 %)     COFACE 16.400 € (+0,24 %)     NEXANS 156.900 € (+1,69 %)     BE SEMICONDUCTOR 265.000 € (+3,96 %)     MEDIANTECHNOLOGIES 5.500 € (0,00 %)     AIRBUS 173.360 € (+2,52 %)     ARKEMA 60.550 € (+0,25 %)     ADP 110.800 € (+5,83 %)     AMG 36.140 € (+2,03 %)     LISI 64.000 € (+3,06 %)     ACCOR 44.960 € (+3,57 %)     HAL TRUST 170.000 € (+1,92 %)     BOUYGUES 50.360 € (+1,31 %)     UNILEVER 49.620 € (-0,10 %)     ARCELORMITTAL SA 53.800 € (+4,96 %)     AIR FRANCE -KLM 10.190 € (+3,16 %)     SANOFI 76.670 € (+1,95 %)     AVANTIUM 8.330 € (+0,48 %)     KERING 248.150 € (+2,86 %)     NOVACYT 0.629 € (-10,65 %)     EXOSENS 61.400 € (+0,99 %)     ING GROEP N.V. 25.965 € (+2,59 %)     RIBER 12.720 € (+6,35 %)     ALSTOM 16.875 € (+0,21 %)     TECHNIP ENERGIES 36.060 € (+1,12 %)     GETLINK SE 18.560 € (+0,71 %)     AALBERTS NV 36.340 € (+2,60 %)     SPIE 48.000 € (+3,09 %)     ASML HOLDING 1 333.000 € (+6,73 %)     MAGNUM 13.712 € (+2,08 %)     CAPGEMINI 101.900 € (-3,23 %)     OPMOBILITY 14.870 € (-1,91 %)     DSM FIRMENICH AG 67.720 € (+1,20 %)     JCDECAUX 18.290 € (+0,77 %)     UBISOFT ENTERTAIN 4.787 € (-6,58 %)     2CRSI 41.400 € (+8,49 %)     ASM INTERNATIONAL 867.600 € (+3,93 %)     NSI N.V. 17.500 € (+0,69 %)     BOIRON 26.900 € (+0,37 %)     ALTAREA 108.200 € (+4,44 %)     MAROC TELECOM 9.140 € (+0,66 %)  
News Réglementées
20/05/2026 16:25

Leo Cancer Care Secures CE Mark for Marie®, Advancing Upright Radiotherapy in Europe

EQS-News: Leo Cancer Care / Key word(s): Product Launch/Miscellaneous
Leo Cancer Care Secures CE Mark for Marie®, Advancing Upright Radiotherapy in Europe

20.05.2026 / 16:25 CET/CEST
The issuer is solely responsible for the content of this announcement.


Leo Cancer Care's CE mark approval for Marie® signals a transformative shift in how radiotherapy is delivered across Europe.

CRAWLEY, England, May 20, 2026 /PRNewswire/ -- Leo Cancer Care today announced that its flagship Marie® upright radiotherapy system has received CE marking, clearing the way for commercial deployment across Europe and marking a significant advancement in how radiotherapy can be delivered. The approval brings to Europe an upright treatment technology that has already gained clinical momentum in the United States.

Marie, Leo Cancer Care's Upright Particle Therapy Solution

A new approach centred on the patient

For decades, radiotherapy has required patients to lie flat and remain still, an approach that has shaped everything from system design to clinical workflows - Marie® rethinks that convention entirely. By enabling treatment in an upright position, Leo Cancer Care is introducing a new paradigm: one designed to truly put the patient at the centre of care.

"This is more than a regulatory milestone - it marks the moment upright radiotherapy becomes a clinical reality for patients in Europe," said Stephen Towe, CEO of Leo Cancer Care, "Marie® redefines what's possible in cancer treatment, combining human-centred design with the flexibility to support both current and emerging treatment modalities."

By enabling upright treatment delivery, Marie also has the potential to simplify treatment room design and improve operational efficiency for cancer centres.

Upright radiotherapy, designed to integrate with emerging and future therapies

Marie® is the first solution of its kind to combine upright patient positioning with a beam-agnostic architecture compatible with multiple particle therapy modalities. This positions Marie® not just as an innovation, but as a future-ready platform for next-generation radiotherapy.

Key potential benefits include:

  • A more natural and comfortable treatment experience for patients
  • Enhanced treatment delivery capabilities, including support for online adaptive and arc therapy
  • Improved accessibility for institutions unable to implement traditional particle therapy solutions
  • A flexible platform designed to support future advances in radiotherapy

Bringing this advanced treatment modality to Europe

CE marking confirms that Marie meets the highest European standards for safety, performance and clinical readiness - the result of years of research, engineering and clinical collaboration with partners across the radiation oncology ecosystem.

Centre Léon Bérard, a hospital that is entirely dedicated to cancer care and research, has been a long-term research partner of Leo Cancer Care. Following CE mark approval, the collaboration will now expand to focus on anatomical imaging and positioning in the upright orientation using Marie's upright CT capabilities.

A pivotal advancement in refining the frontiers of hadrontherapy

For Leo Cancer Care, this milestone is just the beginning, as European installations have begun with Centro Nazionale di Adroterapia Oncologica (CNAO) in Italy, with the aim of commencing treatments before the end of the year.

The Director General of the Centro Nazionale di Adroterapia Oncologica, Dr. Sandro Rossi, remarked on the collaboration with Leo Cancer Care (LCC):

"The integration of the LCC upright positioning system into our clinical workflow marks a transformative milestone for CNAO. By pairing LCC's innovative technology with our horizontal multi-ion beam, we are introducing a sophisticated new modality designed to optimize treatment precision and fundamentally enhance clinical throughput.

This synergy between upright positioning technologies and our clinical expertise does more: it reinforces our commitment to delivering accessible, human-centric, individually tailored and advanced oncological solutions. We look forward to working closely with the Leo Cancer Care team as we move toward installation, commissioning and first patient treatments."

With regulatory approval now in place, Leo Cancer Care is working with other leading cancer centres across Europe to bring upright radiotherapy into clinical practice, accelerating adoption of a solution designed to prioritise both treatment precision and patient experience.

Photo: https://mma.prnewswire.com/media/2984245/LEOCC_Marie.jpg
Logo: https://mma.prnewswire.com/media/2740062/5980168/Leo_Cancer_Care_Logo.jpg

 

Leo Cancer Care Logo (PRNewsfoto/Leo Cancer Care)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/leo-cancer-care-secures-ce-mark-for-marie-advancing-upright-radiotherapy-in-europe-302777824.html

rt.gif?NewsItemId=EN64103&Transmission_Id=202605201019PR_NEWS_EURO_ND__EN64103&DateId=20260520


20.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2330896  20.05.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière